Walther-Jallow L, Andersson S, da Silva Z, Biberfeld G
Swedish Institute for Infectious Disease Control and Microbiology and Tumor Biology Center, Karolinska Institute, Solna.
AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):957-62. doi: 10.1089/088922299310467.
In this study we have evaluated the concordance between serology, using five commercially available antibody assays designed to discriminate between HIV-1 and HIV-2, and the polymerase chain reaction (PCR) for the detection of HIV-1 and HIV-2 dual infection. Thirty-seven HIV-1 and HIV-2 dually reactive serum samples from individuals in Guinea-Bissau with total CD4+ T lymphocyte counts ranging from 9 to 948 x 10(6)/liter were included in the study. All samples were tested by Multispot, Pepti-LAV, and Immunocomb HIV-1 and HIV-2 discriminatory antibody assays. Thirty-two of the 37 samples were also tested by a combination of two HIV type-specific antibody enzyme-linked immunosorbent assays (ELISA; Wellcozyme HIV-1 and Murex HIV-2). Each sample showed dual reactivity in all or any of these assays. A nested PCR based on primer systems in the vif and pol regions of HIV-1 and in the gag and LTR regions of HIV-2 was used to evaluate the serological results. Thirty samples from HIV-1 antibody-positive individuals and 30 samples from HIV-2 antibody-positive individuals were all PCR positive with their corresponding primer systems. The type specificity was 100% for all of the primer systems. The concordance between dual HIV-1 and HIV-2 reactivity on the serological assays and PCR was 77.7% for Multispot, 80% for Pepti-LAV, 81.8% for Immunocomb, and 85.7% for the two ELISAs used in combination. Thus the majority of individuals included in this study appeared to be truly dually infected. The study shows that it is possible, through a careful selection of assays, to reach a high concordance between serological assays and PCR in studying HIV-1 and HIV-2 dual infections.
在本研究中，我们评估了使用五种旨在区分HIV-1和HIV-2的市售抗体检测方法进行的血清学检测与用于检测HIV-1和HIV-2双重感染的聚合酶链反应（PCR）之间的一致性。研究纳入了来自几内亚比绍的37份HIV-1和HIV-2双重反应性血清样本，这些个体的总CD4 + T淋巴细胞计数范围为9至948×10⁶/升。所有样本均通过Multispot、Pepti-LAV以及Immunocomb HIV-1和HIV-2鉴别抗体检测进行检测。37份样本中的32份还通过两种HIV型特异性抗体酶联免疫吸附测定（ELISA；Wellcozyme HIV-1和Murex HIV-2）进行了检测。每个样本在所有或任何这些检测中均显示出双重反应性。基于HIV-1的vif和pol区域以及HIV-2的gag和LTR区域中的引物系统的巢式PCR用于评估血清学结果。来自HIV-1抗体阳性个体的30份样本和来自HIV-2抗体阳性个体的30份样本在其相应的引物系统检测中均为PCR阳性。所有引物系统的类型特异性均为100%。Multispot检测中HIV-1和HIV-2双重反应性在血清学检测与PCR之间的一致性为77.7%，Pepti-LAV为80%，Immunocomb为81.8%，两种ELISA联合使用时为85.7%。因此，本研究中纳入的大多数个体似乎确实为双重感染。该研究表明，通过仔细选择检测方法，在研究HIV-1和HIV-2双重感染时，血清学检测与PCR之间可以达到高度一致性。
